Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd-Reference-Cited by-同舟云学术

Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd

Published:2017-07-12 Issue:2 Volume:179 Page:219-228
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Hughes Timothy P.¹^ORCID,Munhoz Eduardo²,Aurelio Salvino Marco³,Ong Tee Chuan⁴,Elhaddad Alaa⁵,Shortt Jake⁶,Quach Hang⁷,Pavlovsky Carolina⁸,Louw Vernon J.⁹,Shih Lee-Yung¹⁰,Turkina Anna G.¹¹,Meillon Luis¹²,Jin Yu¹³,Acharya Sandip¹⁴,Dalal Darshan¹³,Lipton Jeffrey H.¹⁵

Affiliation:

1. South Australian Health and Medical Research Institute (SAHMRI); University of Adelaide; SA Pathology; Adelaide SA Australia

2. Hospital Erasto Gaertner - Liga Paranaense Combate ao Câncer; Curitiba Brazil

3. Hospital São Rafael-Monte Tabor & Hospital Universitario Professor Edgard Santos-Universidade Federal da Bahia; Salvador Brazil

4. Hospital Ampang; Selangor Malaysia

5. National Cancer Institute; Cairo University; Cairo Egypt

6. School of Clinical Sciences at Monash Health; Monash University; Clayton Vic. Australia

7. St Vincent's Hospital; University of Melbourne; Melbourne Vic. Australia

8. FUNDALEU; Hospitalization and Clinical Research Centre; Buenos Aires Argentina

9. University of the Free State; Bloemfontein South Africa

10. Chang Gung Memorial Hospital-Linkou; Chang Gung University; Taoyuan City Taiwan

11. FGB Haematology Research Centre Health Ministry Research Facility; Moscow Russia

12. Hospital de Especialidades; CMN Siglo XXI; Mexico City Mexico

13. Novartis Pharmaceuticals Corporation; East Hanover NJ USA

14. Novartis Healthcare Pvt. Ltd.; Hyderabad India

15. Princess Margaret Cancer Centre; University of Toronto; Toronto ON Canada

Funder

Novartis Pharmaceuticals Corporation

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14829/fullpdf

Reference22 articles.

1. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet;Baccarani;Journal of Clinical Oncology,2009

2. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013;Baccarani;Blood,2013

3. Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients;Castagnetti;Haematologica,2016

4. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study;Cortes;Journal of Clinical Oncology,2010

5. Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia;Gugliotta;Haematologica,2015

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib;Blood Neoplasia;2024-06

2. Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib;Blood Cancer Journal;2023-09-11

3. The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA;The Lancet Haematology;2022-11

4. Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia;International Journal of Hematology;2022-09-10

5. Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial;Leukemia;2022-08-23